In vitro activity, efficacy, and pharmacology of moxalactam, a new beta-lactam antibiotic.

AUTOR(ES)

Snepar, R

RESUMO

Moxalactam, a potent new beta-lactam antibiotic with a relatively wide spectrum of activity against facultative and anaerobic gram-negative bacilli, was evaluated in vitro and in 28 patients with a variety of severe infections with moxalactam-susceptible organisms (minimum inhibitory concentration less than or equal to 31 microgram/ml). Although therapy was successful in most of these patients, caution is suggested because of the development of resistance on therapy in one patient, persistence of Bacteroides fragilis endocarditis in another, and for certain organisms, a significant inoculum effect on the minimum inhibitory concentration and minimum bactericidal concentration of moxalactam.

Documentos Relacionados

• In vitro activity of temocillin (BRL 17421), a novel beta-lactam antibiotic.
• In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic.
• In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
• In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic.
• Thienamycin: New Beta-Lactam Antibiotic with Potent Broad-Spectrum Activity